Ionis Pharmaceuticals, Inc. IONS
Regular-session close
Pre-market · Nov 20, 4:49 AM ET
- YTD
- -65.59%
- 1 year
- -63.22%
5D -0.39 (-1.41%)
- Market cap
- 4.53B
- Revenue (ttm)
- 960.09M
- Profit margin
- -56.93%
- EPS (ttm)
- -3.35
- Shares out
- 166.55M
- Forward P/E
- -13.43
- YTD return
- -65.59%
- 1-year return
- -63.22%
- 50-day average
- 41.89
- 200-day average
- 63.66
- Volume
- 3.06M
- Avg volume
- 3.89M
- Open
- 27.35
- Previous close
- 27.39
- Day's range
- 26.71 – 27.99
- 52-week range
- 26.55 – 86.74
- Beta
- 0.40
- Analysts
- Buy
- Price target
- 67.83 (+149.2%)
- Earnings date
- Feb 24, 2027
Key statistics
- Enterprise value
- 4.79B
- PEG ratio
- 27.33
- Price / sales
- 4.72
- Price / book
- 11.51
- Revenue growth
- 54.90%
- Free cash flow
- -371.24M
- Total cash
- 1.94B
- Total debt
- 2.17B
- Return on equity
- -108.05%
- Short % of float
- 16.84%
Fundamental scorecard
5 of 25 checks passed on IONS’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 41.00
- Target (mean)
- 67.83
- Target (high)
- 105.00
- Strong buy8
- Buy13
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -0.93444.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -1.36 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -1.23 | -0.66 | +0.57 | +46.34% |
| Jul 29, 2026 | Jun 30, 2026 | -1.09 | -0.69 | +0.40 | +36.70% |
| Apr 29, 2026 | Mar 31, 2026 | -0.85 | -0.56 | +0.29 | +34.12% |
| Feb 25, 2026 | Dec 31, 2025 | -1.24 | -1.41 | -0.17 | -14.02% |
| Oct 29, 2025 | Oct 28, 2025 | -1.15 | -0.61 | +0.54 | +46.96% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2026 | Guggenheim | main | Buy | Buy |
| Nov 10, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Nov 10, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Nov 10, 2026 | TD Cowen | main | Buy | Buy |
| Nov 10, 2026 | Oppenheimer | main | Outperform | Outperform |
| Nov 10, 2026 | RBC Capital | main | Outperform | Outperform |
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ionis.com
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia
Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $65
Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer's disease
TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL
TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)
Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start
Your note
Sign in to keep a note on IONS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAROLDI JOSEPH | Officer | Conversion of Exercise of derivative security | Jun 25, 2026 | 0 |
| BENNETT C FRANK | Officer | Sale | Jul 6, 2026 | 0 |
| BERTHELSEN SPENCER R | Director | Conversion of Exercise of derivative security | Jul 14, 2026 | 161,303 |
| BIRCHLER BRIAN | Officer | Sale | Apr 15, 2026 | 67,500 |
| GEARY RICHARD S | Officer | Conversion of Exercise of derivative security | Nov 5, 2025 | 59,657 |
| HAYDEN MICHAEL REUBEN | Director | Purchase | Jul 30, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.85% | 24,740,108 | 673.43M | Sep 29, 2026 |
| Capital World Investors | 13.08% | 21,787,273 | 593.05M | Sep 29, 2026 |
| Blackrock Inc. | 7.92% | 13,192,834 | 359.11M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.64% | 7,719,464 | 210.12M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.33% | 7,218,530 | 196.49M | Sep 29, 2026 |
| Two Sigma Investments, LP | 4.04% | 6,727,410 | 183.12M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.11% | 8,503,655 | 231.47M | Sep 29, 2026 |
| Growth Fund of America | 4.60% | 7,668,655 | 208.74M | Sep 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.73% | 6,212,640 | 169.11M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 4,989,044 | 135.80M | Jun 29, 2026 |
| New Economy Fund | 2.92% | 4,868,802 | 132.53M | Sep 29, 2026 |
| SmallCap World Fund Inc | 2.68% | 4,458,145 | 121.35M | Sep 29, 2026 |
